Acknowledgements

• John Bradshaw, Glaxo Wellcome, UK.

• Peter Taylor, ICI Pharmaceuticals, UK (retired).

• Peter Kenny, AstraZeneca, UK.

• Dave Weininger, Daylight CIS, USA.

Previous slide

Back to first slide

View graphic version